This product is a kind of PEGylated liposome. The main component of this liposome is Phosphatidylcholine (PC) which is the most abundant phospholipid in eukaryotic cell membranes and it can form lipid bilayers. PEG has been proven to improve the stability of liposomes and increase the circulation time of liposomes in the blood. Therefore, PEGylated liposomes have enhanced tumor permeability and retention effect (EPR) and improved tumor uptake.
Lipid Composition
DSPC DSPE-mPEG2000
Applications
Control liposomes, Membrane biology
Format
Liquid
Concentration
10mg/mL
Hydration Solution
PBS, pH 7.4
External Solution
PBS, pH 7.4
Storage
2°C - 8°C (do not freeze)
Size
70-120 nm
Shelf Life
6 months
Quantity
5mL (available in lyophilized powder)
Dosage
Download
DataSheet
MSDS
FAQsPublished Data Customer ReviewsRelated Sections
What are DSPC:DSPE-mPEG2000 liposomes primarily used for in research?
DSPC:DSPE-mPEG2000 liposomes are often utilized in the delivery of drugs and therapeutic nucleic acids specifically targeting cancer cells. They are designed to enhance the efficacy and reduce systemic toxicity associated with conventional chemotherapy methods. Their stealth characteristics also improve the longevity and accumulation of therapeutic agents at disease sites.
How do the stealth properties of DSPE-mPEG2000 enhance the functionality of these liposomes?
The DSPE-mPEG2000 component in the liposomes contributes stealth properties by extending their circulation time in the bloodstream. This extended presence allows for better accumulation of the liposomes at targeted disease sites, enhancing the overall efficacy of the diagnostic or therapeutic agents they carry.
Are there specific methods recommended for preparing DSPC:DSPE-mPEG2000 liposomes?
These liposomes can be synthesized through standard methods such as thin-film hydration followed by extrusion. This ensures uniform size distribution and optimal encapsulation efficiency, which are critical for their effectiveness as delivery systems.
What are the benefits of using DSPC:DSPE-mPEG2000 liposomes in cancer treatment?
By incorporating targeting ligands or antibodies on their surface, DSPC:DSPE-mPEG2000 liposomes can selectively target cancer cells. This targeted delivery system allows for higher concentrations of anticancer drugs at the tumor site with reduced side effects, increasing the therapeutic index.
How does the composition of DSPC:DSPE-mPEG2000 liposomes affect their stability and delivery capabilities?
The specific lipid composition of DSPC and DSPE-mPEG2000 provides a stable bilayer structure that is crucial for encapsulating and effectively delivering therapeutic agents. The mPEG2000 component enhances the biocompatibility and reduces the immune recognition of the liposomes.
Effect of DcNP vehicle on rate and total uptake of venetoclax (A-C) and zanubrutinib (D-F) into leukemic cells.
This study evaluated the treatment efficacy of venetoclax (Bcl-2 target) and zanubrutinib (BTK target) liposomes in leukemia. Researchers constructed VZ-DCNPs by encapsulating venetoclax and zanubrutinib in DSPC:DSPE-mPEG2000 liposomes. The absorption of free drugs and VZ-DCNPs was studied in three leukemia cells that expressed BTK and Bcl-2 (HL-60 cells), BTK only (K-562 cells), and Bcl-2 only (MOLT-4 cells). The results demonstrated that VZ-DCNPs improved both drugs' absorption in leukemia cells as compared to free drugs, with HL-60 cells demonstrating the greatest absorption. This study highlights the possibility of DSPC:DSPE-mPEG2000 liposomes for combination treatment.
Griffin, James, et al. "Design and Characterization of a Novel Venetoclax-Zanubrutinib Nano-Combination for Enhancing Leukemic Cell Uptake and Long-Acting Plasma Exposure." Pharmaceutics 15.3 (2023): 1016.
Remarkable Drug Stability
Creative Biolabs' DSPC:DSPE-mPEG2000 liposomes significantly enhance drug stability, offering prolonged circulation times, which is critical for effective therapy.
Precision Targeting
The precise targeting capabilities of DSPC:DSPE-mPEG2000 liposomes facilitate targeted drug delivery, crucial for therapies requiring high concentration at specific sites.
Advanced Drug Release
Creative Biolabs' DSPC:DSPE-mPEG2000 liposomes ensure controlled and sustained drug release, improving therapeutic outcomes with reduced side effects.
Enhanced Therapeutic Efficacy
The use of DSPC:DSPE-mPEG2000 liposomes in cancer therapy has shown enhanced therapeutic efficacy, contributing to more effective tumor suppression.
Superior Design and Functionality
Creative Biolabs' DSPC:DSPE-mPEG2000 liposomes exhibit superior design and functionality, supporting complex pharmaceutical applications and research.
Click the button below to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use